Profile data is unavailable for this security.
About the company
Vicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB.
- Revenue in SEK (TTM)104.24m
- Net income in SEK-212.94m
- Incorporated2005
- Employees26.00
- LocationVicore Pharma Holding ABKornhamnstorg 53STOCKHOLM 111 27SwedenSWE
- Phone+46 317880560
- Websitehttps://vicorepharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Infant Bacterial Therapeutics AB | 0.00 | -128.42m | 1.30bn | 9.00 | -- | 4.85 | -- | -- | -9.96 | -9.96 | 0.00 | 20.59 | 0.00 | -- | -- | 0.00 | -37.63 | -16.11 | -43.78 | -16.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -88.03 | -- | -- | -- |
Arcticzymes Technologies ASA | 118.10m | 17.61m | 1.31bn | 68.00 | 74.35 | 4.15 | 54.62 | 11.06 | 0.3443 | 0.3443 | 2.30 | 6.17 | 0.3562 | 0.4228 | 6.29 | 1,731,471.00 | 5.31 | 15.58 | 5.66 | 17.22 | 95.50 | 96.69 | 14.91 | 33.23 | 12.14 | -- | 0.0327 | 0.00 | -13.16 | 12.24 | -40.89 | -- | 47.93 | -- |
Devyser Diagnostics AB | 180.50m | -45.90m | 1.70bn | 124.00 | -- | 4.54 | -- | 9.43 | -2.83 | -2.83 | 11.13 | 23.00 | 0.3671 | 1.56 | 5.11 | 1,529,661.00 | -9.33 | -8.97 | -10.65 | -10.15 | 84.76 | 80.14 | -25.43 | -23.91 | 4.34 | -- | 0.1543 | -- | 33.71 | 28.59 | -16.64 | -- | 44.59 | -- |
Photocure ASA | 514.01m | 4.84m | 1.78bn | 102.00 | 373.90 | 3.68 | 53.71 | 3.47 | 0.1755 | 0.1755 | 19.02 | 17.82 | 0.7215 | 0.9144 | 7.93 | 5,024,010.00 | 0.6789 | -3.06 | 0.7682 | -3.54 | 94.65 | 93.64 | 0.941 | -5.15 | 4.33 | -- | 0.00 | -- | 27.35 | 22.50 | 101.36 | -- | 49.83 | -- |
Nanoform Finland Oyj | 29.29m | -236.93m | 1.92bn | 165.00 | -- | 2.30 | -- | 65.48 | -0.2674 | -0.2674 | 0.0331 | 0.8535 | 0.0287 | 138.93 | 4.11 | 15,548.42 | -23.22 | -27.13 | -25.12 | -29.48 | -507.09 | -604.26 | -809.08 | -1,023.70 | 8.16 | -- | 0.0964 | -- | -26.41 | 61.31 | 5.98 | -- | 53.92 | -- |
XSpray Pharma AB (publ) | 0.00 | -212.58m | 2.04bn | 26.00 | -- | 3.71 | -- | -- | -7.66 | -7.66 | 0.00 | 20.00 | 0.00 | -- | -- | 0.00 | -33.92 | -18.38 | -36.11 | -19.26 | -- | -- | -- | -- | 2.24 | -- | 0.0536 | -- | -- | -- | -36.45 | -- | 2.87 | -- |
Egetis Therapeutics AB (publ) | 62.80m | -326.90m | 2.36bn | 30.00 | -- | 5.00 | -- | 37.64 | -1.22 | -1.22 | 0.2326 | 1.62 | 0.0913 | 28.00 | 4.33 | 2,325,926.00 | -47.48 | -33.02 | -53.33 | -36.46 | 82.17 | -- | -520.22 | -357.72 | 2.53 | -144.77 | 0.2014 | -- | 154.87 | 15.35 | -68.68 | -- | -- | -- |
BioInvent International AB | 61.15m | -334.52m | 2.43bn | 109.00 | -- | 1.97 | -- | 39.76 | -5.08 | -5.08 | 0.929 | 18.73 | 0.041 | -- | 1.29 | 550,927.90 | -22.41 | -17.50 | -23.68 | -18.64 | -- | -- | -547.02 | -131.63 | 13.34 | -- | 0.0169 | -- | -78.09 | 13.14 | -677.13 | -- | 28.17 | -- |
Vicore Pharma Holding AB | 104.24m | -212.94m | 2.46bn | 26.00 | -- | 5.03 | -- | 23.58 | -2.15 | -2.15 | 1.01 | 4.38 | 0.2589 | -- | 14.41 | 4,343,459.00 | -52.89 | -58.65 | -59.34 | -65.58 | -- | -- | -204.27 | -- | -- | -- | 0.00 | -- | -- | -- | -7.81 | -- | -- | -- |
Probi AB | 607.54m | -602.00k | 2.48bn | 167.00 | -- | 1.74 | 25.88 | 4.09 | -0.0528 | -0.0528 | 53.32 | 125.16 | 0.3885 | 3.23 | 6.52 | 3,797,144.00 | -0.0385 | 4.64 | -0.0407 | 4.98 | 32.39 | 42.04 | -0.0991 | 9.83 | 6.22 | -- | 0.0353 | 21.42 | 1.52 | 0.7684 | -58.60 | -26.09 | 31.01 | -- |
Genovis AB | 127.01m | 30.68m | 2.50bn | 36.00 | 81.62 | 12.21 | 60.42 | 19.72 | 0.4686 | 0.4686 | 1.94 | 3.13 | 0.5084 | -- | -- | 3,432,784.00 | 12.28 | 18.56 | 13.37 | 21.45 | 66.09 | 65.51 | 24.15 | 23.88 | -- | -- | 0.2769 | 0.00 | 54.54 | 35.56 | 449.56 | -- | 47.59 | -- |
Hansa Biopharma AB | 165.88m | -844.88m | 3.13bn | 166.00 | -- | -- | -- | 18.90 | -16.07 | -16.07 | 3.15 | -7.10 | 0.1424 | 64.03 | 1.86 | 987,386.90 | -72.51 | -47.96 | -92.27 | -56.12 | 56.80 | 64.18 | -509.33 | -835.04 | 2.55 | -9.65 | 1.65 | -- | -13.22 | 109.06 | -36.09 | -- | -35.24 | -- |
Data as of May 31 2024. Currency figures normalised to Vicore Pharma Holding AB's reporting currency: Swedish Krona SEK
Holder | Shares | % Held |
---|---|---|
Fj�rde AP-fondenas of 03 Jul 2023 | 10.96m | 9.81% |
HBM Partners AG (Investment Management)as of 03 Jul 2023 | 10.87m | 9.73% |
C WorldWide Asset Management Fondsm�glerselskab A/Sas of 31 Dec 2023 | 3.35m | 3.00% |
C Worldwide Asset Management Fondsm�glerselskab A/S (Sweden)as of 31 Aug 2023 | 3.35m | 3.00% |
Tredje AP-fondenas of 30 Jun 2023 | 3.07m | 2.75% |
Swedbank Robur Fonder ABas of 31 Aug 2023 | 2.41m | 2.16% |
Handelsbanken Fonder ABas of 30 Apr 2024 | 2.08m | 1.86% |
Medical Strategy GmbHas of 31 May 2023 | 1.13m | 1.01% |
SEB Investment Management ABas of 30 Apr 2024 | 981.54k | 0.88% |
Andra AP-fondenas of 30 Jun 2023 | 528.75k | 0.47% |
More ▼
Data from 31 Dec 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.